HealthCanadarecentapprobation.

by Brigitte Leonard,Ph.D

HealthCanadaapprovedthreenewsubstancedrugssincethepreviousissues.

Anewoptionforpatientswithdiabetes

Health Canada approved Awiqli, a long-acting insulin (insulin icodec) for treating adults with diabetes, in March 2024. This new insulin developed by Novo Nordisk is more convenient for patients and only allows an injection once weekly. In a clinical trial involving 588 patients with type II diabetes, Awiqli provided superior blood controloveradailytreatmentofover26weeks.

Anewoptionforpatientswithirondeficiency

Health Canada approved FERINJECT (ferric carboxymaltose) in March 2024 distributed by CSL Behring. It is an intravenous fer supplement used to treat iron deficiency anemia (IDA) in oneyear and older patients when oral iron preparations are neither tolerated nor effective. FERINJECT can also treat iron deficiency (ID) in adult patients with heart failure to improve exercise capacity. Iron supplements can be needed when patients have symptoms of iron deficiency, such as low energy, fatigue, lack of concentration, breathlessness during exercise, etc.(2)

A new option for patients with multiple myelomawhofailedseverallinesoftreatment

Despite therapeutic advancements in multiple myeloma, resistance to treatment remains a significant challenge, leading to poor prognostic for many patients. More than 80% of patients with multiple myeloma will suffer from disease progression than die. Most will develop resistance to all three therapeutic classes: IMIDs, antibody therapy (CD-38) and bcl inhibitor. So, newtherapeuticoptionsareneeded.(3)

Health Canada approved Talvey (talquetamab) in April developed by Janssen. The product is approved for treating adult patients with multiple myeloma who have failed at least three prior lines of therapy, including differenttherapeuticclasses.

by Brigitte Leonard,Ph.D

by Brigitte Leonard,Ph.D

Belonging, Diversity, Inclusion and Equity

Welcome to the Belonging, Diversity, Inclusion and Equity section of Heal Canada's Digital Magazine. In this section, we provide information focusing on ensuring that BDEI is part of the patient conversation in our Health ecosystem. Our focus is to illuminate the pathways through which individuals grappling with health challenges can not only find their voice but also harness it to drive their own journey.

Healthcare and the patient experiences should not be determined on social determinants of health.

We believe that an informed and engaged patient is an empowered one, and through enlightening articles, expert insights, and inspiring stories, we aim to equip our readers with the tools and knowledge necessary to navigate the complex landscape of health care.